Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In this Viewpoint, four of our Advisory Board members discuss the key challenges in clinical cancer research that need to be overcome to achieve tangible progress in the next decade. The issues and challenges include clinical development and testing of multiple agents in combination, design of clinical trials, tumour heterogeneity, drug development and trial design, and funding for cancer research. What have we learnt over the past 10 years and how should we progress in the next decade?
In this Viewpoint, four key opinion leaders discuss the slow rate of drug development in paediatric oncology, which must be addressed in a meaningful way if we are to make progress. They discuss a range of aspects, from clinical trial design and biomarker discovery to regulatory amendments and input from industry, government, academia, non-governmental organizations and patient advocacy groups.
